Eko Health Inc.

Eko Health Inc. (Eko) is an American healthcare technology company that develops medical devices, software, and clinical support AI to detect cardiovascular and pulmonary disease.

History
Eko was founded in 2013 by Connor Landgraf, Jason Bellet, and Tyler Crouch. Landgraf was inspired to create Eko after seeing the limitations of traditional stethoscopes during his studies in biomedical engineering at the University of California, Berkeley and recruited his classmates Bellet and Crouch to join him.

In 2015, Eko received FDA clearance for its first product, CORE, a digital attachment for traditional stethoscopes with a compatible smartphone application. In 2017, Eko received FDA clearance for the DUO, a combined digital stethoscope ECG that could be used without a traditional stethoscope. In 2018, Eko's low ejection fraction screening algorithm, developed with the Mayo Clinic, received a ‘Breakthrough Device’ designation from the FDA.

In 2020, Eko announced $65 million in funding, and a collaboration with 3M. Eko raised an additional $30M in funding in 2022, and received FDA clearance for its murmur analysis software.

In 2023, Eko received FDA-clearance for the CORE500 digital stethoscope, which combines artificial intelligence (AI) software, high-fidelity audio, full-color display and 3-lead electrocardiogram (ECG). CORE500 offers compatibility with Eko’s Sensora platform, which uses artificial intelligence (AI) in cardiac disease detection.